American Lung Association (ALA) Lung Health Cohort

Description

The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.

Conditions

Lung Diseases

Talk to us

Study Overview

On this page

Study Details

Study overview

The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.

The American Lung Association (ALA) Lung Health Cohort

American Lung Association (ALA) Lung Health Cohort

Condition
Lung Diseases
Intervention / Treatment

-

Contacts and Locations

Birmingham

University Of Alabama, Birmingham, Alabama, United States, 35294

Tucson

University of Arizona-Tuscon, Tucson, Arizona, United States, 85724

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Aurora

University of Colorado, Aurora, Colorado, United States, 80045

Denver

National Jewish Health, Denver, Colorado, United States, 80206

Jacksonville

Nemours Children's Jacksonville, Jacksonville, Florida, United States, 32207

Jacksonville

University of Florida, Jacksonville, Jacksonville, Florida, United States, 32209

Chicago

University of Illinois at Chicago, Chicago, Illinois, United States, 60608

Chicago

Northwestern University, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Severe asthma, which is defined as any of the following:
  • 1. Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = \>250 fluticasone, propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS.
  • 2. 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
  • 3. One asthma hospitalization in the past 12 months
  • 2. History of any chronic lung disease other than asthma including but not limited to COPD, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
  • 3. Current pregnancy
  • 4. History of cancer other than non-melanoma skin cancer
  • 5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)
  • 6. Inability to comply with study procedures, including
  • 1. Inability or unwillingness to provide informed consent
  • 2. Inability to perform study measurements
  • 3. Inability to be contacted by phone (via calls and/or text messaging) or email
  • 7. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).
  • 8. Institutionalization

Ages Eligible for Study

25 Years to 35 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Johns Hopkins University,

Ravi Kalhan, MD, PRINCIPAL_INVESTIGATOR, Northwestern University

Study Record Dates

2026-09